ACOD1 enzyme in immune cells that help prostate cancer grow
Cis-aconitate decarboxylase (ACOD1) in PMN-MDSC and prostate cancer progression
Looks at whether blocking ACOD1 in certain immune cells could help men with advanced prostate cancer respond better to hormone and immune therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11247994 on NIH RePORTER |
What this research studies
Researchers are focusing on ACOD1, an enzyme in a type of immune cell (PMN-MDSCs) that can suppress the body's anti-cancer immune response in prostate cancer. They will examine tumor and blood samples from patients and use laboratory mouse models to see whether reducing ACOD1 activity lessens immune suppression. The team plans to combine ACOD1-targeting approaches with anti-androgen treatment and immune checkpoint therapies to see if the combinations improve control of tumors. Results will help decide whether future clinical trials should test ACOD1-targeting treatments in people with resistant prostate cancer.
Who could benefit from this research
Good fit: Men with advanced or metastatic prostate cancer, especially those whose disease is not responding well to anti-androgen therapy or immunotherapy, are the most likely candidates for related trials.
Not a fit: People with early-stage localized prostate cancer or those without prostate cancer are unlikely to benefit directly from this work.
Why it matters
Potential benefit: If successful, this could make immunotherapy and hormone treatments work better and slow progression in some men with advanced prostate cancer.
How similar studies have performed: Prior preclinical and some clinical work suggests targeting suppressive myeloid cells can improve therapy responses, but specifically targeting ACOD1 is a newer approach still mainly tested in lab models.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Wang, Guocan — University of Tx Md Anderson Can Ctr
- Study coordinator: Wang, Guocan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.